Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

Completed Research Project

Investigator(s):

Sarah M. Cheal, Ph.D.

Related Institute:

Molecular Imaging Innovations Institute (MI3)

Last Updated:

June 7, 2022

We developed the α-emitter DOTA-ligand bound radionucleuide-based pre-targeted radioimmunotherapy (DOTA-PRIT) with 225Ac and the requisite companion biomarkers (111In, 89Zr). Please see Theranostics: 2020, 10(25):11359-11375 and Nucl. Med. and Biol.: 2021, 96: p. S3-S4.